Alumis Inc. Common Stock
HealthcareNASDAQ:ALMS · NASDAQ Global Select
+$3.25 today
Vol 2.22M · Avg 1.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-80.8%
avg -22.7%
ROIC
-120.2%
avg -141.6%
ROA
-59.1%
avg -105.4%
Analysis
ROA is currently the strongest return metric at -59.1% versus its period average of -105.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Martin Babler | President, Chief Executive Officer & Chairman | $1.21M | — | 61 | $745,875.00 | 0.60% |
David Goldstein | Chief Scientific Officer | $821,186.00 | — | 60 | $216,675.00 | 0.18% |
Jorn Drappa | Chief Medical Officer & Head of Research and Development | $817,058.00 | — | 61 | $164,465.00 | 0.13% |
Roy C. Hardiman | Chief Business & Strategy Officer | $619,841.00 | — | 66 | $190,875.00 | 0.15% |
Jack Danilkowicz | Chief Commercial Officer | — | — | — | — | — |
John R. Schroer | Chief Financial Officer | — | — | 61 | $202,225.00 | 0.16% |
Mark Bradley | Chief Development Officer | — | — | 60 | $190,225.00 | 0.15% |
Grace Halteh | Senior Vice President & Head of Quality and Regulatory | — | — | — | — | — |
Sanam Pangali | Chief Legal Officer & Corporate Secretary | — | — | 42 | $186,200.00 | 0.15% |
Kolbot By | Senior Vice President & Head of Technical Operations | — | — | — | — | — |
Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader | — | — | — | — | — |
Claire Langrish | Senior Vice President & Head of Immunology and Translational Science | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
36
$50.95M
Sells
0
$0.00
Net Sentiment
+$50.95M
Net buying
Most Active
AKKARAJU SRINIVAS
15 transactions
1–10 of 36
Analysis
Insiders reported 36 buys worth $50.95M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $50.95M. AKKARAJU SRINIVAS was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +105.2% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +105.2% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
$865.32M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages ALMS?
Alumis Inc. Common Stock (ALMS) lists 12 active executives. The top listed executive is Jorn Drappa, Chief Medical Officer & Head of Research and Development.
Are ALMS insiders buying or selling?
Recent insider activity shows net buying of $113.33M.
Explore More
Continue the stock analysis
Jump to another research area for this company.